Clinical Trials for Other Solid Tumor

A Phase I Study of Intraperitoneal 5FU+Oxaliplatin in Patients with Colorectal Cancer with Isolated Peritoneal Metastasis

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with biopsy-proven colorectal cancer and isolated peritoneal metastases (PCI >20), without prior cytoreductive surgery, who receive intraperitoneal oxaliplatin and 5FU via a peritoneal port. It is designed to assess safety, tolerability, and dose parameters of this locoregional chemotherapy approach.

ClinicalTrials.gov ID: NCT06269978

Phase II Study of Infliximab for the Treatment of Immune Checkpoint Inhibitor Colitis

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Eligible patients are adults with stage III or IV skin cancer who develop endoscopically confirmed colitis after CTLA-4 inhibitor (± PD-1/PD-L1) therapy; they will be randomized to receive either infliximab, a TNF-α inhibitor, or standard corticosteroids, with crossover allowed for inadequate response.

ClinicalTrials.gov ID: NCT04305145

Phase II Trial of Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With Metastatic Colorectal Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with left-sided, unresectable, metastatic, mismatch repair–proficient colorectal cancer without KRAS, NRAS, or BRAF V600 mutations to study panitumumab or cetuximab, alone or with chemotherapy, as early-line therapy, retreatment, or rechallenge based on prior anti-EGFR and chemotherapy exposure. Patients are assigned to cohorts according to their prior response and exposure to EGFR inhibitors and FOLFOX.

ClinicalTrials.gov ID: NCT04587128

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with advanced or metastatic, microsatellite stable colorectal cancer harboring a KRAS G12C mutation who have progressed on at least one prior line of chemotherapy are eligible for combination therapy with adagrasib (a selective KRAS G12C inhibitor), cetuximab (anti-EGFR antibody), and cemiplimab (PD-1 inhibitor). Prior exposure to KRAS G12C or immune checkpoint inhibitors is excluded.

ClinicalTrials.gov ID: NCT06412198

Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with unresectable, locally advanced, metastatic, or recurrent mesothelioma (epithelioid or biphasic with >80% epithelioid), or other solid tumors with high mesothelin expression (≥50% of tumor cells), who have progressed after standard therapies. Treatment involves lymphodepleting chemotherapy followed by a single infusion of autologous CAR T cells (TNhYP218) engineered to target a membrane-proximal epitope of mesothelin, using naive/stem cell memory T cells to potentially enhance efficacy.

ClinicalTrials.gov ID: NCT06885697

A Phase I/IIa, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumor Activity of H002 in Patients With Active EGFR Mutation Locally Advanced or Metastatic NSCLC

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adults with unresectable locally advanced or metastatic NSCLC harboring active EGFR mutations, including C797S, who have progressed on osimertinib or another third-generation EGFR-TKI, receiving the investigational fourth-generation EGFR tyrosine kinase inhibitor H002 to assess its safety and preliminary anti-tumor activity.

ClinicalTrials.gov ID: NCT05519293

A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial evaluates ABSK112, a small molecule targeting EGFR exon 20 insertion mutations, in patients with locally advanced or metastatic non-small cell lung cancer characterized by these mutations, focusing on its safety, tolerability, and pharmacokinetics. The study involves dose escalation and an expansion cohort, enrolling adults with measurable disease and a life expectancy of at least three months.

ClinicalTrials.gov ID: NCT06225804

A Modular, Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients With Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial involves patients who are postmenopausal women with relapsed locally advanced or metastatic AR+/HER2-/ER+ breast cancer, focusing on the safety and efficacy of EP0062 (vosilasarm), a selective androgen receptor modulator. Participants must have previously treated, inactive cancer and meet specific cardiac and medication criteria.

ClinicalTrials.gov ID: NCT05573126

A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves patients with metastatic or recurrent non-small cell lung cancer who have progressed after platinum-doublet chemotherapy and PD-1/PD-L1 blockade, testing a combination therapy of pembrolizumab (anti-PD-1), ramucirumab (anti-VEGF receptor), and docetaxel.

ClinicalTrials.gov ID: NCT04340882

A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial involves adult patients with advanced or metastatic solid tumors, including those with non-small cell lung cancer (NSCLC), breast, and colorectal cancer, particularly focusing on NSCLC with EGFR mutations during dose expansion, testing CPO301, an EGFR-targeting antibody-drug conjugate.

ClinicalTrials.gov ID: NCT05948865